VANIA LORVANIS: Open Payments
NPI 1386259018 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$456 in 20 payments from 12 companies in 2025. Trend: 2023 $215 · 2024 $1,303 · 2025 $456
Food & beverage: $456
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 7 | $140 |
| Madrigal Pharmaceuticals | 1 | $108 |
| Novo Nordisk Inc | 2 | $35 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
| GlaxoSmithKline, LLC. | 1 | $22 |
| Exact Sciences Corporation | 1 | $20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Corcept Therapeutics | 1 | $17 |
Products named: REZDIFFRA, LEQVIO, ENTRESTO, Ozempic, TRELEGY ELLIPTA, Cologuard Collection Kit, XIFAXAN, REXULTI.
Industry payments across NY — which companies pay providers there.
